SHENZHEN, Guangdong, CHINA, 30 June 2026 — Consider the brake. Not the engine, which gets all the attention, but the brake, the quiet thing that decides how fast a system is allowed to go. A new Thought Leaders Invited Review in Brain Medicine argues that the brain keeps such a brake, a small peptide called somatostatin, and that stress works much of its harm by tampering with it. The review breaks no new experimental ground. It does something rarer. It gathers fifty years of scattered findings and holds them to the light until a single shape appears.
A discovery that arrived backward
Somatostatin was found by people looking for its opposite. In 1973, Brazeau and his colleagues were chasing a substance that would release growth hormone. What they caught instead was a fourteen amino acid peptide that did the reverse and shut the hormone off. The molecule has been saying no ever since. The review follows it out of the pituitary and into the brain proper, where evolution put it to subtler work, a neurotransmitter that tunes how cleanly one neuron speaks to the next. Two versions travel the body, SST-14 and SST-28. Five kinds of receptor listen. Why would a brain bother to build so much machinery devoted to restraint? Because a mind without brakes is not free. It is simply out of control.
The cells that hold the line
In the cortex, where excitement could easily feed on itself and spiral, somatostatin lives inside a class of inhibitory neurons that make up close to a third of all interneurons in many regions. They are easy to overlook. They fire low and steady rather than loud, and they pour out somatostatin alongside GABA, the standard quieting signal of the brain, so that two brakes press at once. The review maps where their influence runs. These cells lean on other interneurons, touch the large pyramidal neurons that do the heavy lifting of the cortex, and stretch long wires into distant territory. Pull those wires and behavior shifts. Quiet them and the animal grows fearful, or freezes, or loses the appetite for pleasure.
Stress does not push, it sculpts
This is where assembling the whole literature pays off. Read one stress study and you see one result. Read two hundred, as the authors have, and a grammar emerges. Stress does not move somatostatin in a single direction, up or down. It carves. A sudden shock can flood the dentate gyrus with the peptide within minutes. Weeks of mild, grinding stress do the opposite, thinning the ranks of somatostatin neurons in the hippocampus while the animal stops seeking sweetness, stops trying. Predator odor, an open maze, restraint, lost sleep, early separation from a mother, each presses its own thumbprint into a different region, the amygdala, the prefrontal cortex, the zona incerta, the bed nucleus of the stria terminalis, the septum.
"What becomes visible only when you assemble the whole literature is that somatostatin neurons are not bystanders in stress," said Dr. Hongling Guo, the corresponding author, who works in the School of Chemical Biology and Biotechnology at Peking University Shenzhen Graduate School. "They are selectively vulnerable to it. And that vulnerability falls on the very circuits that decide mood."
Wires, not islands
For a long time neuroscience could do little more than count these cells and note their absence. Now it can reach in and flip single connections on and off, and the review gives its center to what that has revealed. Somatostatin neurons turn out to be junctions rather than islands. In the central amygdala they gate fear by reaching toward the zona incerta and the periaqueductal gray. In the zona incerta they sit wired between the anterior cingulate cortex and the lateral habenula, and depending on which thread is tightened, an animal sinks toward despair or climbs out of it.
"In our own work on the zona incerta, chronic restraint stress quieted these neurons, and switching them back on produced antidepressant-like effects," Dr. Guo said. "The same shape kept appearing in region after region. That is finally what made a review feel necessary."
The fine print of sex
Below the circuits lies the chemistry, and the review reads it closely. When researchers sequenced somatostatin neurons one cell type at a time, they found that chronic stress rewrites the genetic output of those cells along different lines in males and females. Genes for making GABA, for cyclic signaling inside the cell, for sensing glutamate, for hearing acetylcholine, for catching growth hormone, all turn up in the account. One finding refuses to leave.
"The sex differences run through almost every level we looked at, from the transcriptome to the behavior," said Dr. Shupeng Li, a co-author at the Functional Microbiology Research and Development Center, Research Institute of Tsinghua University in Shenzhen. "Something that rescues a male animal can do nothing in a female, or the reverse. No honest therapy can ignore that."
When the brake gives way
The human chapters are harder reading. In postmortem brains and spinal fluid, depression shows up again and again as a loss, less somatostatin, fewer of the neurons that carry it, and in women the loss tends to cut deeper than in men. The same shortfall trails through bipolar disorder, schizophrenia, Alzheimer disease, Parkinson disease, and one form of epilepsy. Then comes the exception that keeps the story honest. In post-traumatic stress disorder the peptide runs high rather than low. Is the missing somatostatin a cause of these illnesses, a consequence of them, or a scar they happen to share? The review will not pretend to know. It asks the question cleanly and lets it stand.
A gentler class of medicine
If somatostatin helps set the temperature of feeling, can a drug turn the dial? The review lays the options on the table without overselling them. Ketamine and scopolamine, the two fast antidepressants that have unsettled psychiatry in recent years, appear to do part of their work through these very interneurons. A shelf of somatostatin analogs already exists, octreotide, lanreotide, and pasireotide among them, built mostly for tumors and hormones rather than for grief.
"We have a growing catalog of somatostatin analogs, and not one of them is approved for a stress related disorder of the brain," said Dr. Tahir Ali, a co-author at Peking University Shenzhen Graduate School. "The reasons are stubbornly practical. The molecules degrade, or they cannot cross the blood brain barrier. The review names those walls instead of pretending they are doors."
What the light does not yet reach
No good synthesis ends in a victory lap, and this one closes on the dark water at the edge of the lamp. How does chronic stress actually carve a somatostatin neuron, circuit by circuit, before a mood disorder ever announces itself? Do these neurons speak to the non-neuronal cells of the brain during stress, and if so, in what tongue? Can a gene be delivered into them precisely enough, and safely enough, to help a patient rather than a mouse? The authors close by naming their debt. The review appears as part of a special Festschrift issue of Brain Medicine honoring Dr. Seymour Reichlin, whose work across nearly eight decades shaped the understanding of hypothalamic-pituitary regulation and of the inhibiting factors, somatostatin chief among them. There is a kind of rhyme in that. The molecule he helped place on the map is still, half a century on, redrawing the map itself.
The peer-reviewed review article in Brain Medicine titled "Somatostatin regulation of the stress response," is freely available via Open Access, starting on 30 June 2026 in Brain Medicine at the following hyperlink: https://doi.org/10.61373/bm026i.0042 .
The full reference for citation purposes is: Guo H, Ali T, Li S. Somatostatin regulation of the stress response. Brain Medicine 2026. DOI: https://doi.org/10.61373/bm026i.0042 . Epub 2026 Jun 30.
About Brain Medicine: Brain Medicine (ISSN: 2997-2639, online and 2997-2647, print) is a peer-reviewed medical research journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal's scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.
Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/
Our media website is at: https://media.genomicpress.com/
Our full website is at: https://genomicpress.com/
